Drug Trial News

RSS
New drug zilebesiran effectively lowers blood pressure for six months, study finds

New drug zilebesiran effectively lowers blood pressure for six months, study finds

Single injection of new medication effectively eliminates Lp(a) for nearly one year

Single injection of new medication effectively eliminates Lp(a) for nearly one year

SELECT trial: Semaglutide reduces cardiovascular events by 20% in overweight or obese patients without diabetes

SELECT trial: Semaglutide reduces cardiovascular events by 20% in overweight or obese patients without diabetes

AdvanCell reaches milestone as first prostate cancer patient dosed with 212Pb-ADVC001

AdvanCell reaches milestone as first prostate cancer patient dosed with 212Pb-ADVC001

Clinical trial underway for novel human milk-based microbiome therapy

Clinical trial underway for novel human milk-based microbiome therapy

Obinutuzumab shows promise in preserving kidney function, preventing flares in lupus nephritis patients

Obinutuzumab shows promise in preserving kidney function, preventing flares in lupus nephritis patients

Mucosal vaccine shows lasting defense against SARS-CoV-2 Omicron in primate study

Mucosal vaccine shows lasting defense against SARS-CoV-2 Omicron in primate study

FORTE accrues first 1000 participants for highly anticipated colorectal cancer prevention trial

FORTE accrues first 1000 participants for highly anticipated colorectal cancer prevention trial

Patients with advanced HER2-positive breast cancer live longer if treated with pyrotinib, trial shows

Patients with advanced HER2-positive breast cancer live longer if treated with pyrotinib, trial shows

Study compares the immunogenicity and safety of two SARS-CoV-2 vaccines

Study compares the immunogenicity and safety of two SARS-CoV-2 vaccines

UTHSC's drug candidate for advanced prostate cancer goes to first clinical trial

UTHSC's drug candidate for advanced prostate cancer goes to first clinical trial

Targeted drug may offer a new treatment option for patients with relapsed blood cancer

Targeted drug may offer a new treatment option for patients with relapsed blood cancer

Sotagliflozin provides kidney and heart benefits in patients with diabetes and chronic kidney disease

Sotagliflozin provides kidney and heart benefits in patients with diabetes and chronic kidney disease

High-impact clinical trial results  to be presented at ASN Kidney Week 2023

High-impact clinical trial results to be presented at ASN Kidney Week 2023

Docetaxel improves survival in men with high-grade prostate cancer and low PSA

Docetaxel improves survival in men with high-grade prostate cancer and low PSA

Clinical trial demonstrates the effectiveness of ALS drug in treating people with acute spinal cord injuries

Clinical trial demonstrates the effectiveness of ALS drug in treating people with acute spinal cord injuries

The development of a machine-learned scoring function of human preference in the context of early drug discovery campaigns

The development of a machine-learned scoring function of human preference in the context of early drug discovery campaigns

University of Cincinnati to lead NIH StrokeNet for next five years

University of Cincinnati to lead NIH StrokeNet for next five years

New treatment combination shows promise for metastatic colorectal cancer patients with rare genetic mutation

New treatment combination shows promise for metastatic colorectal cancer patients with rare genetic mutation

Breast cancer screening trial expands internationally to enhance diversity

Breast cancer screening trial expands internationally to enhance diversity

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.